General Prescription Drugs News

« Previous Entries

FDA Gives Approval to Endari to Treat Sickle Cell Disease

Sunday, July 16th, 2017

The FDA has given its approval to Endari for reducing serious complications linked to sickle disease in patients aged 5 years or more. Sickle Disease is a term used to describe a group of genetic red blood disorders. Sickle disease patients have abnormal hemoglobin, a protein responsible for carrying oxygen all across the body, in […]

FDA Gives Approval to Zinbryta for Treating Multiple Sclerosis

Saturday, May 28th, 2016

The FDA gave approval to Zinbryta for treating adults suffering relapsing remitting forms of multiple sclerosis. Administered in form of an injection, Zinbryta is administered once monthly. Multiple sclerosis or MS belongs to the category of autoimmune diseases. It is a chronic, inflammatory condition marked by disruptive communication between brain and other body parts. While […]

FDA Gives Approval to Probuphine for Treating Opioid Dependency

Friday, May 27th, 2016

The FDA has given approval to Probuphine, which is the first buprenorphine implant, to be used as a maintenance treatment in cases of opioid dependency. Probuphine works by providing a consistent low-dose of buprenorphine for a period of six months. It is to be used in patients who are already stable using low to moderate […]

FDA Gives Approval to Tecentriq to Treat Urothelical Carcinoma

Tuesday, May 24th, 2016

The FDA has given approval to Tecentriq for treating urothelial carcinoma, the most common type of cancer of the urinary system. Tecentriq belongs to the class of drugs called PD-1/PD-L1 inhibitors and is the first drug of its class to receive approval for this bladder cancer. Tecentriq works by targeting specific proteins, called PD-1/PD-L1 pathway, […]

MS Drug Might Increase Colorectal Cancer Risk

Friday, May 13th, 2016

A recent study points a link between the use of mitoxantrone in multiple sclerosis patients and an increased risk of colorectal cancer. Mitoxantrone is approved for use in those multiple sclerosis patients who have failed to get an adequate response from other therapies. The drug reduces disease relapses by inhibiting the patient’s immune system and […]

FDA Gives Approval to Nuplazid for Treating Hallucinations & Delusions Linked to Parkinson Disease

Friday, May 6th, 2016

The FDA has given approval to Nuplazid for treating hallucinations and delusions experienced by Parkinson’s disease patients because of their underlying psychotic condition. Nuplazid is the first drug that has received approval from the FDA for treating hallucinations and delusions linked with psychosis. It is estimated that half of Parkinson’s patients experience hallucinations (defined as […]

FDA Gives Approval to a New Drug for Treating Some Chronic Lymphocytic Patients

Tuesday, April 12th, 2016

The FDA has given approval to Venclexta for treating patients who have chronic lymphocytic leukemia as well as a specific chromosomal abnormality known as 17p deletion and who have undergone one earlier therapy at the minimum. Venclexta works by targeting BCL-2 protein. This protein is found to support the growth of cancer cells and is […]

Long-term Use of Pioglitazone Might Increase Risk of Bladder Cancer

Friday, April 8th, 2016

Does pioglitazone, a popular medication for type 2 diabetes, increases the chance of developing cancer of bladder or not is a question that has once again shot into the limelight, thanks to a new study probing the link between the drug and bladder cancer risk. This, however, is not the first study on this subject. […]

FDA Gives Its Nod to First Leadless Peacemaker For Treating Heart Rhythm Disorders

Wednesday, April 6th, 2016

The FDA has given approval to the first leadless peacemaker for treating heart rhythm disorders. Unlike other peacemakers, Micra Transcatheter Pacing System does not use lead wires for providing an electrical connection between the device and patient’s heart. This self-contained device is no more than an inch long and is installed in the heart’s right […]

FDA Gives Approval to Inflectra

Tuesday, April 5th, 2016

The FDA has given its approval to Inflectra for more than one indication. This drug is administered intravenously and is the 2>nd biosimilar to receive approval from the FDA. Biosimilar to Remicade, Inflectra can be used for the treatment of: Patients (adult as well as pediatric patients who are above 6 years of age) who […]

« Previous Entries